Loomis, Sayles & Company
ALXN

Loomis, Sayles & Company’s Alexion Pharmaceuticals ALXN Stock Holding History

Loomis, Sayles & Company’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-18,480
Closed -$1.8M – 904
2018
Q4 		$1.8M Sell
18,480
-18,237
-50% -$2.16M ﹤0.01% 520
2018
Q3 		$5.1M Sell
36,717
-84,276
-70% -$10.6M 0.01% 476
2018
Q2 		$15M Sell
120,993
-58,299
-33% -$6.81M 0.03% 316
2018
Q1 		$20M Sell
179,292
-3,038
-2% -$363K 0.04% 247
2017
Q4 		$21.8M Buy
182,330
+64,275
+54% +$7.83M 0.05% 247
2017
Q3 		$16.6M Sell
118,055
-47,497
-29% -$6.45M 0.04% 325
2017
Q2 		$20.1M Buy
165,552
+83,549
+102% +$9.72M 0.05% 254
2017
Q1 		$9.94M Sell
82,003
-80,051
-49% -$10.3M 0.02% 420
2016
Q4 		$19.8M Sell
162,054
-33,280
-17% -$4.07M 0.05% 266
2016
Q3 		$23.9M Sell
195,334
-22,360
-10% -$2.88M 0.06% 209
2016
Q2 		$25.4M Sell
217,694
-374,785
-63% -$53.2M 0.07% 204
2016
Q1 		$82.5M Buy
592,479
+43,568
+8% +$6.4M 0.23% 60
2015
Q4 		$105M Buy
548,911
+59,344
+12% +$10.4M 0.3% 47
2015
Q3 		$76.6M Buy
489,567
+70,243
+17% +$12.8M 0.23% 69
2015
Q2 		$75.8M Buy
+419,324
New +$72.4M 0.21% 80
2014
Q1 		– Sell
-22,106
Closed -$2.94M – 789
2013
Q4 		$2.94M Buy
+22,106
New +$2.65M 0.01% 583

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Loomis, Sayles & Company's ALXN Position: Q1 2019 in Review

Loomis, Sayles & Company sold out of Alexion Pharmaceuticals (ALXN) in Q1 2019, closing a stake of 18,480 shares — an estimated $1.8M sold.

Loomis, Sayles & Company first reported a position in ALXN in Q4 2013 and held it in 16 quarters. The position peaked at $105M in Q4 2015. 612 funds tracked by Wall St. Rank hold ALXN as of Q1 2019.

  • Loomis, Sayles & Company reported no remaining Alexion Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Loomis, Sayles & Company sold 18,480 Alexion Pharmaceuticals shares in Q1 2019, an estimated $1.8M.
  • Loomis, Sayles & Company first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 16 quarters.
  • Loomis, Sayles & Company's Alexion Pharmaceuticals position peaked at $105M in Q4 2015.
  • 612 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2019.

Based on Loomis, Sayles & Company's 13F filing for Q1 2019, filed 15 May 2019.